Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in RLAY.

← Back to Free Index

RLAY

Analysis as of: 2026-07-07

Relay Therapeutics, Inc.

Clinical-stage biotech using its Dynamo discovery engine to develop small-molecule medicines for genetically defined cancers and genetic diseases.

ai biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Proof Story With Two Real Expansion Legs

The setup is attractive because one molecule could anchor two commercial businesses and validate the discovery engine. The catch is that current valuation already assumes real success, so the next five years are about proving a franchise, not just interesting biology.

Analysis

Thesis

Relay can roughly double by 2031 if zovegalisib graduates from a promising Phase 3 asset into a focused franchise across later-line breast cancer, early vascular anomalies, and a credible frontline path; the non-linearity comes from one molecule validating both commercial value and the broader discovery engine.

Last Economy Alignment

Cheaper cognition helps Relay design drugs faster, but value is still captured through IP, clinical proof, and FDA trust rather than software seats or agent workflows.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.8x (from 5 most recent analyses)

Reasoning

A double is plausible because one approved drug could support two real businesses and keep a larger frontline option alive. I do not underwrite a 5-10x outcome because the market already prices meaningful success, the company is still concentrated in one lead asset, and clinical or regulatory slippage would delay the compounding loop.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

This is mainly a concentrated proof story, not a software disruption story. If zovegalisib wins randomized data, secures a workable regulatory path, and converts into a combo-based commercial franchise, valuation can scale meaningfully. If the data soften or the frontline path slips, the company lacks enough diversification or recurring revenue to cushion the de-rate.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material company-specific press release or SEC filing surfaced in the last 7-10 days, so the core thesis is unchanged.
No new FDA update has appeared on the planned frontline Phase 3 design, leaving early 2027 as the same main visible repricing gate.
With no fresh fundamental news, recent strength appears to reflect continued digestion of the spring clinical updates and financing.

Forecast update

Upside is less asymmetric than before because the stock has rerated sharply while the core clinical and regulatory gates remain largely the same.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.29

They use computation and proprietary lab data to design better drugs, so AI helps them work faster. But they only get paid if the medicine wins in trials and regulators agree, which keeps the score positive but far from elite.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$24.25

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research